Gene therapy of severe combined immunodeficiency disease: Proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome;Thérapie génique des déficits immunitaires sévères: Preuve de principe d'efficacité et problèmes soulevés. Thérapie génique, déficits immunitaires, rétrovirus, lentivirus, génome

Bulletin de l'Academie Nationale de Medecine

Volumn 189, Issue 5, 2005, Pages 779-788

  Fischer, Alain ^a   Hacein Bey Abina, Salima ^b   Lagresle, Chantal ^b   Garrigue, Alexandrine ^b   Cavazana Calvo, Marina ^b   Binet, M Jacques Louis ^b   Vacheron, M André ^b   Bach, M Jean François ^b   Sraer, M Jean Daniel ^b   Ardaillou, M Raymond ^b   Sureau, M Claude ^b   Galibert, M Francis ^b   Pessac, M Bernard ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE

Author keywords

Gene therapy; Genome; Immunologie deficiency; Lentivirus; Retroviridae; Syndromes

Indexed keywords

EID: 29544433568     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)33504-6     Document Type: Review

References (24)

1. MULLIGAN RC. - The basic science of gene therapy. Science 1993, 260, 926-32.
2. CAVAZZANA-CALVO M., LAGRESLE C., HACEIN-BEY-ABINA S., FISCHER A. - Gene therapy of severe combined immunodeficiency. Ann. Review of Medicine, 2005, 56, 585-602.
3. FISCHER A., HACEIN-BEY-ABINA S., CAVAZZANA-CALVO M. - Gene therapy for immunodeficiency diseases. Semin. Hematol., 2004, 41, 272-8.
4. LEONARD WJ. - Cytokines and immunodeficiency diseases. Nature. Review. Immunology., 2001, 1, 200-208.
5. FISCHER A., HACEIN-BEY S., CAVAZZANA-CALVO M. - Gene therapy of severe combined immunodeficiencies. Nat. Rev. Immunol., 2002, 2, 615-21.
6. CAVAZZANO-CALVO M., HACEIN-BEY S., DE SAINT BASILE G., GROSS F, YVON E., NUSBAUM P., SELZ F., HUE C., CERTYAIN S., CASANOVA J.L., BOUSSO P., DEIST F.L., FISCHER A. - Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. equal contribution. Science, 2000, 288, 669-72.
7. HACEIN-BEY-ABINA S., LE DEIST F., CARLIER F., BOUNEAUD C., HUE C., DE VILLARTAY J.P., THRASHER A.J., WULFFRAAT N., SORENSEN R., DUPUIS-GIROD S., FISCHER A., CAVAZZANA-CALVO M. - Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med., 2002, 346, 1185-93.
8. SSCHMIDT M., HACEIN-BEY-ABINA S., WISSLER M., CARLIER F., LIM A., PRINZ C., GLIMM H., ANDRÉ-SCHMUTZ I., HUE C., GARRIGUE A., LE DEIST F., LAGRESLE C., FISCHER A., CAVAZZANA-CALVO M., VON KALLE C. - Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood, 2004, 7 : 7.
9. GASPAR H.B., PARSLEY K.L., HOWE S., KING D., GILMOUR K.C., SINCLAIR J., BROUNS G., SCHMIDT M., VON KALLE C., BARINGTON T., JAKOBSEN M.A., CHRISTENSEN H.O., AL GHONAIUM A., WHITE H.N., SMITH J.L., LEVINSKY RJ., ALI RR., KINNON C., THRASHER AJ. - Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet, 2004, 364, 2181-7.
10. AIUTI A., SLAVIN S., AKER M., FICARA F., DEOLA SARINELLO E., CATTANEO F., VAI S., SERVUDA P., MINIERO R., RONCAROLO M.G., BORDIGNON C. - Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 2002, 296, 2410-3.
11. YATES F., MALASSIS-SERIS M., STOCKHOLM D., BOUNEAUD C., LAROUSSERIEF., NOGUIEZ-HELLIN P., DANOS O., KOHN D.B., FISCHER A., DE VILLARTAY JP., CAVAZZANA-CALVO M. - Gene therapy of RAG-2-/- mice : sustained correction of the immunodeficiency. Blood, 2002, 22 : 22.
12. KLEIN C., NGUYEN D., LIU CH., MIZOGUCHI A., BHAN AK., MIKI H., TAKENAWA T., ROSEN FS., ALT FW., MULLIGAN RC., SNAPPER SB. - Gene therapy for Wiskott-Aldrich syndrome : rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood, 2003, 101, 2159-66.
13. GOEBEL WS., DINAUER MC. - Gene therapy for chronic granulomatous disease. Acta Haematol, 2003, 110, 86-92.
14. MAY C., RIVELLA S., CALLEGARI J., HELLER G., GAENSLER KM., LUZZATTO L., SADELAIN M. - Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature, 2000, 406, 82-6.
15. HACEIN-BEY-AABINA S., VON KALLE C., SCHMIDT M., MCCORMACK MP., WULFFRAAT N., LEBOULCH P., LIM A., OSBORNE CS., PAWLIUK R., MORILLON E., SORENSEN R., FORSTER A., FRASER P., COHEN JI., DE SAINT BASILE G., ALEXANDER I., WINTERGERSTS U., FREBOURG T., AURIAS A., STOPPA-LYONNET D., ROMANA S., RADFORD-WEISS I., GROSS F., VALENSI F., DELABESSE E., MACINYRE E., SIGAUX F., SOULIER J., LEIVA LE., WISSLER M., PRINZ C., RABBITTS TH., LE DEIST F., FISCHER A., CAVAZZANA-CALVO M. - LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1. Science, 2003, 302, 415-9 - equal contribution.
16. FISCHER A., ABINA SH., THRASHER A., VON KALLE C., CAVAZZANA-CALVO M. - LMO2 and gene therapy for severe combined immunodeficiency. N. Engl. J. Med., 2004, 350, 2526-7 ; author reply 2526-7.
17. SCHRODER AR., SHINN P., CHEN H., BERRY C., ECKER JR., BUSHMAN F. - HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 2002, 110, 521-9.
18. WU X., LI Y., CRISE B., BURGESS SM. - Transcription start regions in the human genome are favored targets for MLV integration. Science, 2003 300 1749-51.
19. LI Z., DULLMANN J., SCHIEDLMEIER B., SCHMIDT M., VON KALLE C., MEYER J., FORSTER M., STOCKING C., WAHLERS A., FRANK O., OSTERTAG W., KUHLCKE K., ECKERT HG., FEHSE B., BAUM C. - Murine leukemia induced by retroviral gene marking. Science, 2002 296, 497.
20. DAVE UP., JENKINS NA., COPELAND NG. - Gene therapy insertional mutagenesis insights. Science, 2004, 303, 333.
21. KIRN D., NICULESCU-DUVAZ I., HALLDEN G., SPRINGER CJ. - The emerging fields of suicide gene therapy and virotherapy. Trends. Mol. Med., 2002, 8, S68-73.
22. CHUNG JH., BELL AC., FELSENFELD G. - Characterization of the chicken beta-globin insulator. Proc. Natl. Acad. Sci., U S A 1997, 94, 575-80.
23. OLIVARES EC., HOLLIS RP., CHALBERG TW., MEUSE L., KAY MA., CALOS MP. - Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat. Biotechnol., 2002, 20, 1124-8.
24. PORTEUS MH., CATHOMEN T., WEITZMAN MD., BALTIMORE D. - Efficient gene targeting mediated by adeno-associated virus and DNA double-strand breaks. Mol. Cell. Biol., 2003, 23, 3558-65.